The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Pathological growth of cardiomyocytes (hypertrophy) is a major determinant for the development of heart failure, one of the leading medical causes of mortality worldwide. Here we show that the microRNA (miRNA)-212/132 family regulates cardiac hypertrophy and autophagy in cardiomyocytes. Hypertrophic stimuli upregulate cardiomyocyte expression of miR-212 and miR-132, which are both necessary and sufficient to drive the hypertrophic growth of cardiomyocytes. MiR-212/132 null mice are protected from pressure-overload-induced heart failure, whereas cardiomyocyte-specific overexpression of the miR-212/132 family leads to pathological cardiac hypertrophy, heart failure and death in mice. Both miR-212 and miR-132 directly target the anti-hypertrophic and pro-autophagic FoxO3 transcription factor and overexpression of these miRNAs leads to hyperactivation of pro-hypertrophic calcineurin/NFAT signalling and an impaired autophagic response upon starvation. Pharmacological inhibition of miR-132 by antagomir injection rescues cardiac hypertrophy and heart failure in mice, offering a possible therapeutic approach for cardiac failure. Heart failure is often a consequence of pathological growth of cardiomyocytes or cardiac hypertrophy. Here Ucar and colleagues report that the microRNAs miR-132 and miR-212 promote cardiac hypertrophy and inhibit autophagy in cardiomyocytes by downregulating the transcription factor FoxO3.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, fine-tuning of FOXO3 levels has been achieved via a miRNA-132 antagonistic approach,157 that is currently clinically tested (NCT04045405).”
From Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis (2020) · cites this paper as [157]
In the citing paper
“| Cardiomyopathies | Cardiomyocyte‐specific overexpression of miR‐212/132 | Pathological cardiac hypertrophy, heart failure, and premature death, after impaired autophagic response upon starvation | Ucar et al (2012) |”
From Autophagy in major human diseases (2021) · cites this paper as Ucar et al (2012)
In the citing paper
“Along similar lines, the cardiomyocyte‐specific overexpression of miRNAs invalidating the transcriptional activity of FOXO3 (Ucar et al, 2012) or activating MTORC1 (Li et al, 2017) precipitates cardiac function, leading to heart failure.”
From Autophagy in major human diseases (2021) · cites this paper as Ucar et al, 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Rockman, H. A., Ross, R. S., Harris, A. N., Knowlton, K. U., Steinhelper, M. E., Field, L. J., Ross, J., & Chien, K. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.18.8277 · Cited by 797
RetractedMicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S. H., & Goldberg, A. L. (2004) · Cell · doi:10.1016/s0092-8674(04)00400-3 · Cited by 3,012
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., et al. (2008) · Nature · doi:10.1038/nature07511 · Cited by 2,349
Self-citationHomeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice.
Komatsu, M., Waguri, S., Koike, M., Sou, Y.-S., Ueno, T., Hara, T., Mizushima, N., Iwata, J.-I., Ezaki, J., Murata, S., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.035 · Cited by 2,124
Jung, C. H., Ro, S.-H., Cao, J., Otto, N. M., & Kim, D.-H. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.01.017 · Cited by 2,090
Control of translation and mRNA degradation by miRNAs and siRNAs: Table 1.
Valencia-Sanchez, M. A., Liu, J., Hannon, G. J., & Parker, R. (2006) · Genes & Development · doi:10.1101/gad.1399806 · Cited by 2,060
Control of Stress-Dependent Cardiac Growth and Gene Expression by a MicroRNA
van Rooij, E., Sutherland, L. B., Qi, X., Richardson, J. A., Hill, J., & Olson, E. N. (2007) · Science · doi:10.1126/science.1139089 · Cited by 1,657
Ventura, A., Young, A. G., Winslow, M. M., Lintault, L., Meissner, A., Erkeland, S. J., Newman, J., Bronson, R. T., Crowley, D., Stone, J. R., et al. (2008) · Cell · doi:10.1016/j.cell.2008.02.019 · Cited by 1,590
Cited by
Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches
Beermann, J., Piccoli, M.-T., Viereck, J., & Thum, T. (2016) · Physiological Reviews · doi:10.1152/physrev.00041.2015 · Cited by 1,726
“Both in genetic and pharmacological deletion models, miR-132 silencing shows therapeutic efficacy to block cardiac remodeling by normalization of cardiac size and inhibition of fibrosis (266), paving the way for potential future clinical trials to block pathological cardiac remodeling in patients.”
BackgroundSelf-citationAutophagy in major human diseases
Klionsky, D. J., Petroni, G., Amaravadi, R. K., Baehrecke, E. H., Ballabio, A., Boya, P., Bravo‐San Pedro, J. M., Cadwell, K., Cecconi, F., Choi, A. M. K., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108863 · Cited by 1,585
Bang, C., Batkai, S., Dangwal, S., Gupta, S. K., Foinquinos, A., Holzmann, A., Just, A., Remke, J., Zimmer, K., Zeug, A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70577 · Cited by 979
“Transfection of miR-132 served as a positive control (26).”
Self-citationPhysiological and pathological cardiac hypertrophy
Shimizu, I., & Minamino, T. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2016.06.001 · Cited by 887
Autophagy and mitophagy in cardiovascular disease
Bravo-San Pedro, J. M., Kroemer, G., & Galluzzi, L. (2017) · Circulation Research · doi:10.1161/circresaha.117.311082 · Cited by 843
“Moreover, mice engineered to overexpress miR-212 and miR-132—2 miRNAs that inhibit the proautophagic transcription factor FOXO3 (forkhead box O3)(42)—in cardiomyocytes succumbed prematurely owing to pathological cardiac hypertrophy and heart failure.(36) A similar cardiac hypertrophy has been observed in mice overexpr…”
BackgroundmiRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges
Zhou, S.-S., Jin, J.-P., Wang, J.-Q., Zhang, Z.-G., Freedman, J. H., Zheng, Y., & Cai, L. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2018.30 · Cited by 675
The Role of Autophagy in the Heart
Sciarretta, S., Maejima, Y., Zablocki, D., & Sadoshima, J. (2018) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021317-121427 · Cited by 547
Täubel, J., Hauke, W., Rump, S., Viereck, J., Batkai, S., Poetzsch, J., Rode, L., Weigt, H., Genschel, C., Lorch, U., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa898 · Cited by 393
“The mechanism of action of CDR132L is to prevent and revert pathological cardiac remodelling as described earlier.(3,5,6) A summary of the mode of action is provided in the Take home figure.”
BackgroundSelf-citationLong Noncoding RNAs and MicroRNAs in Cardiovascular Pathophysiology
Thum, T., & Condorelli, G. (2015) · Circulation Research · doi:10.1161/circresaha.116.303549 · Cited by 385
“Both genetic and pharmacological inhibition of miR-132 rescued cardiac hypertrophy and HF in mice, offering a possible therapeutic approach for this pathology.(28) In addition, microRNAs regulate intracellular calcium homeostasis, directly contributing to cardiac contractility.”
BackgroundSelf-citationmicroRNAs in Cardiovascular Diseases
Condorelli, G., Latronico, M. V. G., & Cavarretta, E. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.050 · Cited by 375
“induced by pressure overload via TAC (126)”
Long noncoding RNA Chast promotes cardiac remodeling
Viereck, J., Kumarswamy, R., Foinquinos, A., Xiao, K., Avramopoulos, P., Kunz, M., Dittrich, M., Maetzig, T., Zimmer, K., Remke, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf1475 · Cited by 370
“Plekhm1 has been shown to impede autophagy in various cell lines (16), and inhibition of autophagy in cardiomyocytes drives cardiac remodeling processes (17, 18).”
BackgroundSelf-citationLong noncoding RNAs in cardiac development and ageing
The Cardiolinc network (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.55 · Cited by 341
Autophagy: Regulation and role in development
Hale, A. N., Ledbetter, D. J., Gawriluk, T. R., & Rucker, III (2013) · Autophagy · doi:10.4161/auto.24273 · Cited by 336
Adult-specific functions of animal microRNAs
Sun, K., & Lai, E. C. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3471 · Cited by 334
RNA-based diagnostic and therapeutic strategies for cardiovascular disease
Lu, D., & Thum, T. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0218-x · Cited by 331
Self-citationAutophagy in cardiovascular biology
Lavandero, S., Chiong, M., Rothermel, B. A., & Hill, J. A. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73943 · Cited by 331
“Recently, Ucar et al. showed that the miRNA-212/132 family regulates both cardiac hypertrophy and autophagy by targeting FoxO3 (61), adding to the growing body of evidence for a crucial role of autophagy in the con-trol of hypertrophy.”
MicroRNAs in Heart Failure: From Biomarker to Target for Therapy
Vegter, E. L., van der Meer, P., de Windt, L. J., Pinto, Y. M., & Voors, A. A. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.495 · Cited by 303
The miRNA Plasma Signature in Response to Acute Aerobic Exercise and Endurance Training
Nielsen, S., Åkerström, T., Rinnov, A., Yfanti, C., Scheele, C., Pedersen, B. K., & Laye, M. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087308 · Cited by 297
Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles
Bonora, M., Wieckowski, M. R., Sinclair, D. A., Kroemer, G., Pinton, P., & Galluzzi, L. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0074-0 · Cited by 294
Wong, H.-K. A., Veremeyko, T., Patel, N., Lemere, C. A., Walsh, D. M., Esau, C., Vanderburg, C., & Krichevsky, A. M. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt164 · Cited by 271
Pathophysiological implications of hypoxia in human diseases
Chen, P.-S., Chiu, W.-T., Hsu, P.-L., Lin, S.-C., Peng, I.-C., Wang, C.-Y., & Tsai, S.-J. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00658-7 · Cited by 318
“Similarly, anti-miR-92a and antimiR-132 therapies are also effectively resistant to hypoxia-induced cardiac injury [13, 155].”
BackgroundMicroRNA Therapeutics: the Next Magic Bullet?
Simonson, B., & Das, S. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666150324123208 · Cited by 263
“In cardiac pathological hypertrophy, miR-212/132 is overexpressed and involved in the pathological phenotype [10].”
BackgroundLekka, E., & Hall, J. (2018) · FEBS Letters · doi:10.1002/1873-3468.13182 · Cited by 251
Non-coding RNAs in Cardiac Remodeling and Heart Failure
Kumarswamy, R., & Thum, T. (2013) · Circulation Research · doi:10.1161/circresaha.113.300226 · Cited by 249
Self-citationAutophagy and oxidative stress in cardiovascular diseases
Mei, Y., Thompson, M. D., Cohen, R. A., & Tong, X. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.05.005 · Cited by 243
“MiR-212/132 deletion protects mice from pressure-overload-induced heart failure [89].”
BackgroundCardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling
Sassi, Y., Avramopoulos, P., Ramanujam, D., Grüter, L., Werfel, S., Giosele, S., Brunner, A.-D., Esfandyari, D., Papadopoulou, A. S., De Strooper, B., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01737-4 · Cited by 234
Self-citationmiR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo
Smith, P. Y., Hernandez-Rapp, J., Jolivette, F., Lecours, C., Bisht, K., Goupil, C., Dorval, V., Parsi, S., Morin, F., Planel, E., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv377 · Cited by 220
MicroRNA-132 enhances transition from inflammation to proliferation during wound healing
Li, D., Wang, A., Liu, X., Meisgen, F., Grünler, J., Botusan, I. R., Narayanan, S., Erikci, E., Li, X., Blomqvist, L., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79052 · Cited by 231
“Next, we validated the importance of miR-132 for skin wound healing in vivo by using a miR-132–KO mouse line, which has been previously characterized with regard to its resistance to pressure overload–induced heart failure (28) and experimental autoimmune encephalomyelitis (43).”
MethodSelf-citationGarcia, N. A., Ontoria-Oviedo, I., González-King, H., Diez-Juan, A., & Sepúlveda, P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138849 · Cited by 229
“Culture in-St conditions resulted in exosome loading of several miRNAs, some of which have been associated with exosome microRNA patterns (miRNA-17, 20a, 23b, 30b, 132) [35, 36].”
BackgroundmiRNA Therapeutics: A New Class of Drugs with Potential Therapeutic Applications in the Heart
Bernardo, B. C., Ooi, J. Y., Lin, R. C., & McMullen, J. R. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.107 · Cited by 226
Preclinical development of a miR-132 inhibitor for heart failure treatment
Foinquinos, A., Batkai, S., Genschel, C., Viereck, J., Rump, S., Gyöngyösi, M., Traxler, D., Riesenhuber, M., Spannbauer, A., Lukovic, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14349-2 · Cited by 212
Self-citationPreclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease
Huang, C.-K., Kafert-Kasting, S., & Thum, T. (2020) · Circulation Research · doi:10.1161/circresaha.119.315856 · Cited by 210
Self-citationAutophagy is a regulator of TGF-β1-induced fibrogenesis in primary human atrial myofibroblasts
Ghavami, S., Cunnington, R. H., Gupta, S., Yeganeh, B., Filomeno, K. L., Freed, D. H., Chen, S., Klonisch, T., Halayko, A. J., Ambrose, E., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.36 · Cited by 207
“In other cardiac diseases (such as hypertension), globalized fibrosis is likely a primary contributor to the progression of congestive heart failure.(63) It is well known that TGF-β1 is expressed in the heart 64 and that, following MI, the levels of TGF-β1 are increased in the scar area.”
BackgroundSelf-citationLi, H., Fan, J., Zhao, Y., Zhang, X., Dai, B., Zhan, J., Yin, Z., Nie, X., Fu, X.-D., Chen, C., et al. (2019) · Circulation Research · doi:10.1161/circresaha.119.314898 · Cited by 208
“18 Conversely, miR-21 was reported to show increased expression in fibroblasts but remained unchanged in myocytes during heart failure.”
Colpaert, R. M. W., & Calore, M. (2019) · Cells · doi:10.3390/cells8070737 · Cited by 195
“miR-212/132 family Upregulated Hypertrophy [40]”
BackgroundInfluentialmiR-199a impairs autophagy and induces cardiac hypertrophy through mTOR activation
Li, Z., Song, Y., Liu, L., Hou, N., An, X., Zhan, D., Li, Y., Zhou, L., Li, P., Yu, L., et al. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2015.95 · Cited by 191
“Although a considerable number of miRNAs are shown to be key regulators of autophagy,(13) only a few miRNAs participating in cardiac autophagy have been discovered until recently.(14,15) Nevertheless, how miRNAs regulate cardiac autophagy and cardiac hypertrophy is underexplored.”
BackgroundMicroRNA profiling unveils hyperglycaemic memory in the diabetic heart
Costantino, S., Paneni, F., Lüscher, T. F., & Cosentino, F. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv599 · Cited by 190
Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis
Stojanović, S. D., Fiedler, J., Bauersachs, J., Thum, T., & Sedding, D. G. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz919 · Cited by 188
Self-citationExosomal transfer of miR-30a between cardiomyocytes regulates autophagy after hypoxia
Yang, Y., Li, Y., Chen, X., Cheng, X., Liao, Y., & Yu, X. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1387-2 · Cited by 185
“family regulates both cardiac hypertrophy and cardiomyocyte autophagy by targeting the anti-hypertrophic and proautophagic Foxo3 transcription factor directly [6].”
BackgroundMyocardial stress and autophagy: mechanisms and potential therapies
Delbridge, L. M. D., Mellor, K. M., Taylor, D. J., & Gottlieb, R. A. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.35 · Cited by 178
Substrate recognition in selective autophagy and the ubiquitin–proteasome system
Schreiber, A., & Peter, M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.03.019 · Cited by 177
Lavenniah, A., Luu, T. D. A., Li, Y. P., Lim, T. B., Jiang, J., Ackers-Johnson, M., & Foo, R. S.-Y. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.04.006 · Cited by 175
“It was recently shown that miR212/132 family expression is upregulated in cardiomyocytes following hypertrophic stimuli and miR-212/132 necessarily drive pathological hypertrophy.(17) Pharmacological targeting of miR-132 by antagomiRs reduces cardiac hypertrophy progression, and abrogates heart failure in rodent model…”
BackgroundResultInfluentialAutophagy in the diabetic heart: A potential pharmacotherapeutic target in diabetic cardiomyopathy
Dewanjee, S., Vallamkondu, J., Kalra, R. S., John, A., Reddy, P. H., & Kandimalla, R. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101338 · Cited by 174
MicroRNA-221 inhibits autophagy and promotes heart failure by modulating the p27/CDK2/mTOR axis
Su, M., Wang, J., Wang, C., Wang, X., Dong, W., Qiu, W., Wang, Y., Zhao, X., Zou, Y., Song, L., et al. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.187 · Cited by 172
Cardiovascular autophagy: Concepts, controversies, and perspectives
Lavandero, S., Troncoso, R., Rothermel, B. A., Martinet, W., Sadoshima, J., & Hill, J. A. (2013) · Autophagy · doi:10.4161/auto.25969 · Cited by 172
Current Advances in RNA Therapeutics for Human Diseases
Zogg, H., Singh, R., & Ro, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052736 · Cited by 172
The Role of MicroRNAs in Myocardial Infarction: From Molecular Mechanism to Clinical Application
Sun, T., Dong, Y.-H., Du, W., Shi, C.-Y., Wang, K., Tariq, M.-A., Wang, J.-X., & Li, P.-F. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040745 · Cited by 166
“Further studies identified that transcription factor FoxO3 is a target of miR-212/132 in autophagic signal pathway [64].”
BackgroundMolecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy
Evangelista, I., Nuti, R., Picchioni, T., Dotta, F., & Palazzuoli, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133264 · Cited by 165
“miR-1 [69,75] Downregulated Hypertrophy and oxidative stress Cardiac and skeletal muscle miR-1/206 [71] Upregulated Cardiomyocytes apoptosis Cardiac muscle miR-34a [71,74] Upregulated Cardiomyocytes apoptosis Cardiac muscle miR-133a [69] Downregulated Hypertrophy and oxidative stress Cardiac and skeletal muscle miR-19…”
BackgroundMir-30d Regulates Cardiac Remodeling by Intracellular and Paracrine Signaling
Li, J., Salvador, A. M., Li, G., Valkov, N., Ziegler, O., Yeri, A., Yang Xiao, C., Meechoovet, B., Alsop, E., Rodosthenous, R. S., et al. (2021) · Circulation Research · doi:10.1161/circresaha.120.317244 · Cited by 165
MicroRNA and Cardiovascular Diseases
Çakmak, H. A., & Demir, M. (2020) · Balkan Medical Journal · doi:10.4274/balkanmedj.galenos.2020.2020.1.94 · Cited by 160
CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure
Bátkai, S., Genschel, C., Viereck, J., Rump, S., Bär, C., Borchert, T., Traxler, D., Riesenhuber, M., Spannbauer, A., Lukovic, D., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa791 · Cited by 163
“Transgenic mice overexpressing the miR-212/132 cluster develop pathological cardiac remodelling and die prematurely from progressive HF.(4) Further studies by our group showed that miR-132 is both necessary and sufficient to drive the pathological growth of cardiomyocytes and we proposed to develop a therapeutic strat…”
BackgroundResultInfluentialSelf-citationRNA Therapeutics in Cardiovascular Disease
Lucas, T., Bonauer, A., & Dimmeler, S. (2018) · Circulation Research · doi:10.1161/circresaha.117.311311 · Cited by 173
Gene Therapy for the Heart Lessons Learned and Future Perspectives
Cannata, A. N., Ali, H., Sinagra, G., & Giacca, M. (2020) · Circulation Research · doi:10.1161/circresaha.120.315855 · Cited by 161
Dangwal, S., Stratmann, B., Bang, C., Lorenzen, J. M., Kumarswamy, R., Fiedler, J., Falk, C. S., Scholz, C. J., Thum, T., & Tschoepe, D. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.305048 · Cited by 158
Self-citationMicroRNAs as therapeutic targets in cardiovascular disease
Laggerbauer, B., & Engelhardt, S. H. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159179 · Cited by 167
“Genetic deficiency of the miR-132/-212 cluster or an antagomir against miR-132-3p prevented TAC-induced pathologic cardiac remodeling (87).”
BackgroundMethodSelf-citationRemenyi, J., van den Bosch, M. W. M., Palygin, O., Mistry, R. B., McKenzie, C., Macdonald, A., Hutvagner, G., Arthur, J. S. C., Frenguelli, B. G., & Pankratov, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062509 · Cited by 143
“In addition, deletion of miR-132 and miR-212 in mice has shown a role for these miRNAs in mammary gland development [12] and cardiovascular function [21].”
BackgroundOverview of MicroRNAs in Cardiac Hypertrophy, Fibrosis, and Apoptosis
Wang, J., Liew, O. W., Richards, M., & Chen, Y. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050749 · Cited by 153
Hernandez-Rapp, J., Rainone, S., Goupil, C., Dorval, V., Smith, P. Y., Saint‐Pierre, M., Vallée, M., Planel, E., Droit, A., Calon, F., et al. (2016) · Scientific Reports · doi:10.1038/srep30953 · Cited by 144
Role of cell death in the progression of heart failure
Moe, G. W. P. L., & Marín-García, J. (2016) · Heart Failure Reviews · doi:10.1007/s10741-016-9532-0 · Cited by 148
Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure
Dirkx, E., Gladka, M. M., Philippen, L. E., Armand, A., Kinet, V., Leptidis, S., el Azzouzi, H., Salic, K., Bourajjaj, M., da Silva, G. J. J., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2866 · Cited by 141
Self-citationNon-Coding RNA-Targeted Therapy: A State-of-the-Art Review
Nappi, F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073630 · Cited by 146
MicroRNA: A new therapeutic strategy for cardiovascular diseases
Samanta, S., Balasubramanian, S., Rajasingh, S., Patel, U., Dhanasekaran, A., Dawn, B., & Rajasingh, J. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2016.02.004 · Cited by 135
“Studies have shown that miRNA-212 and miRNA-132 families have major roles in both cardiac hypertrophy and cardiomyocyte autophagy by regulating Fox signaling pathway [86].”
Preclinical development of a MicroRNA-based therapy for elderly patients with myocardial infarction
Gupta, S. K., Foinquinos, A., Thum, S., Remke, J., Zimmer, K., Bauters, C., de Groote, P., Boon, R. A., de Windt, L. J., Preissl, S., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.07.739 · Cited by 125
Self-citationMiR‐451 is decreased in hypertrophic cardiomyopathy and regulates autophagy by targeting TSC 1
Song, L., Su, M., Wang, S., Zou, Y., Wang, X., Wang, Y., Cui, H., Zhao, P., Hui, R., & Wang, J. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12380 · Cited by 136
Autophagy during cardiac remodeling
Nishida, K., & Otsu, K. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.12.003 · Cited by 130
Burek, M., König, A., Lang, M., Fiedler, J., Oerter, S., Roewer, N., Bohnert, M., Thal, S. C., Blecharz-Lang, K. G., Woitzik, J., et al. (2019) · Translational Stroke Research · doi:10.1007/s12975-018-0683-2 · Cited by 126
Self-citationNon-Coding RNAs Including miRNAs and lncRNAs in Cardiovascular Biology and Disease
Kataoka, M., & Wang, D. (2014) · Cells · doi:10.3390/cells3030883 · Cited by 118
“…[9] miR-208 Med13 cardiac hypertrophy, reprogramming of fibroblasts into cardiomyocyte-like cells [18] miR-212 FoxO3 cardiac hypertrophy [59] miR-214 Slc8a1, Bcl2l11, Ppif cardiac remodeling [60] miR-320 Hsp6b myocardial ischemia [41] miR-328 Cacna1c, Cacnb1 atrial fibrillation [61]…”
BackgroundNoncoding RNA in age-related cardiovascular diseases
Greco, S., Gorospe, M., & Martelli, F. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.01.011 · Cited by 120
“miR-132/212 family Inhibition, KO Protection from pressure overload-induced heart failure [208]”
BackgroundAutophagy and Hallmarks of Cancer
Huang, T., Song, X., Yang, Y., Wan, X., Alvarez, A. A., Sastry, N. G., Feng, H., Hu, B., & Cheng, S. (2018) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2018027913 · Cited by 128
Function and Therapeutic Potential of Noncoding RNAs in Cardiac Fibrosis
Creemers, E. E., & van Rooij, E. (2015) · Circulation Research · doi:10.1161/circresaha.115.305242 · Cited by 118
Zou, M., Wang, F., Gao, R., Wu, J., Ou, Y., Chen, X., Wang, T., Zhou, X. Y., Zhu, W., Li, P., et al. (2016) · Scientific Reports · doi:10.1038/srep24747 · Cited by 117
Xu, C., Hu, Y., Hou, L., Ju, J., Li, X., Du, N., Guan, X., Liu, Z., Zhang, T., Qin, W., et al. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.07.009 · Cited by 113
Development of Long Noncoding RNA-Based Strategies to Modulate Tissue Vascularization
Fiedler, J., Breckwoldt, K., Remmele, C. W., Hartmann, D., Dittrich, M. T., Pfanne, A., Just, A., Xiao, K., Kunz, M., Müller, T., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.081 · Cited by 121
“Numerous reports have proved that single miRs have a master role in the regulation of cardiovascular pathophysiology and serve as interesting treatment targets (1,2).”
BackgroundSelf-citationHeart regeneration: 20 years of progress and renewed optimism
Garbern, J. C., & Lee, R. T. (2022) · Developmental Cell · doi:10.1016/j.devcel.2022.01.012 · Cited by 116
Lu, D., Chatterjee, S., Xiao, K., Riedel, I., Huang, C.-K., Costa, A., Cushman, S., Neufeldt, D., Rode, L., Schmidt, A., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac337 · Cited by 114
“Design and efficacy of Circ-INSR therapy in a murine in vivo model of doxorubicin-induced cardiotoxicity To test the therapeutic potential of Circ-INSR in vivo, we employed a previously established mouse model of chronic doxorubicin-induced cardiotoxicity.(29,31,32) We produced AAV9-Circ-INSR and control AAV9-Empty vi…”
MethodSelf-citationCardiomyocyte‐secreted acetylcholine is required for maintenance of homeostasis in the heart
Roy, A., Fields, W. C., Resende, C. R., Resende, R. R., Guatimosim, S., Prado, V. F., Gros, R., & Prado, M. A. M. (2013) · The FASEB Journal · doi:10.1096/fj.13-238279 · Cited by 133
“leads to pathological cardiac hypertrophy (44).”
microRNA Therapeutics in Cardiovascular Disease Models
Dangwal, S., & Thum, T. (2013) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135957 · Cited by 112
Self-citationTargeting Myocardial Remodelling to Develop Novel Therapies for Heart Failure
Tarone, G., Balligand, J., Bauersachs, J. K., Clerk, A., Windt, L. J. D., Heymans, S. R. B., Hilfiker‐Kleiner, D., Hirsch, E., Iaccarino, G., Knöll, R., et al. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.62 · Cited by 114
Self-citationCardiovascular microRNAs: as modulators and diagnostic biomarkers of diabetic heart disease
Rawal, S., Manning, P. J., & Katare, R. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-44 · Cited by 111
“Cardiac hypertrophy Conversely, miR-132 along with miR-212 was found to be upregulated in cardiomyocytes following hypertrophic stimuli [56].”
BackgroundThe emergence of noncoding RNAs as Heracles in autophagy
Zhang, J., Wang, P., Wan, L., Xu, S., & Pang, D. (2017) · Autophagy · doi:10.1080/15548627.2017.1312041 · Cited by 106
de Gonzalo‐Calvo, D., Vea, À., Bär, C., Fiedler, J., Couch, L. S., Brotons, C., Llorente‐Cortés, V., & Thum, T. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy234 · Cited by 105
“Accordingly, the manipulation of ncRNA expression has emerged as a novel and promising therapeutic approach.(23,24) Of note, clinical tri-”
BackgroundSelf-citationRole of microRNA in diabetic cardiomyopathy: From mechanism to intervention
Guo, R., & Nair, S. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.03.013 · Cited by 106
microRNA in Cardiovascular Aging and Age-Related Cardiovascular Diseases
de Lucia, C., Komici, K., Borghetti, G., Femminella, G. D., Bencivenga, L., Cannavò, A., Corbi, G., Ferrara, N., Houser, S. R., Koch, W. J., et al. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00074 · Cited by 112
“The role of miR-146 is controversial: some authors found miR-146 to be upregulated TABLe 2 | Summarizing table of main effects of different microRNAs (miRNAs) reported in the text within specific cardiac remodeling characteristics. miRNA Cardiac remodeling implication effect Reference miR-1 Cardiomyocyte hypertrophy A…”
BackgroundInfluentialMehta, A., Zhao, J. L., Sinha, N., Marinov, G. K., Mann, M., Kowalczyk, M. S., Galimidi, R. P., Du, X., Erikci, E., Regev, A., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.05.017 · Cited by 95
Self-citationEmerging Actors in Diabetic Cardiomyopathy: Heartbreaker Biomarkers or Therapeutic Targets?
Palomer, X., Pizarro‐Delgado, J., & Vázquez‐Carrera, M. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.02.010 · Cited by 96
Signaling cascades in the failing heart and emerging therapeutic strategies
He, X., Du, T., Long, T., Liao, X., Dong, Y., & Huang, Z. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00972-6 · Cited by 112
“The miRNA-212/ 132 family has been suggested to have a hypertrophic effect.(110) Targeting the miR-212/132 family using ASOs (antagomiR-212/ 132) was successful in treating heart failure in a pig model.”
MethodThe role of microRNAs in heart failure
Wang, H., & Cai, J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.11.034 · Cited by 98
Rogg, E.-M., Abplanalp, W. T., Bischof, C., John, D., Schulz, M. H., Krishnan, J., Fischer, A., Poluzzi, C., Schaefer, L., Bonauer, A., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034598 · Cited by 92
Tocchetti, C. G., Ameri, P., de Boer, R. A., D’Alessandra, Y., Russo, M., Sorriento, D., Ciccarelli, M., Kiss, B., Bertrand, L., Dawson, D. K., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa222 · Cited by 99
Self-citationMicroRNAs in infectious diseases: potential diagnostic biomarkers and therapeutic targets
Kimura, M., Kothari, S. P., Gohir, W., Camargo, J. F., & Husain, S. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00015-23 · Cited by 106
Ramalinga, M., Roy, A., Srivastava, A., Bhattarai, A., Harish, V., Suy, S., Collins, S., & Kumar, D. (2015) · Oncotarget · doi:10.18632/oncotarget.5920 · Cited by 96
“miR-212 has been shown earlier to modulate autophagy in cardiomyocytes [40].”
Backgroundvan der Velden, J., Asselbergs, F. W., Bakkers, J., Bátkai, S., Bertrand, L., Bezzina, C. R., Bot, I., Brundel, B. J. J. M., Carrier, L., Chamuleau, S. A. J., et al. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvab370 · Cited by 105
Self-citationFunctions of Autophagy in Pathological Cardiac Hypertrophy
Li, Z., Wang, J., & Yang, X. Y. (2015) · International Journal of Biological Sciences · doi:10.7150/ijbs.11883 · Cited by 97
“Intravenously injection of specific antagomirs against miR-132, an autophagy-inhibiting miRNA, rescues pressure overload-induced cardiac hypertrophy and heart failure in mice [87].”
BackgroundLi, Q., Xie, J., Li, R., Shi, J., Sun, J., Gu, R., Ding, L., Wang, L. Y., & Xu, B. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12242 · Cited by 94
MicroRNA Control of High-Density Lipoprotein Metabolism and Function
Rayner, K. J., & Moore, K. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.300645 · Cited by 101
MicroRNA as a Therapeutic Target in Cardiac Remodeling
Chen, C., Ponnusamy, M., Liu, C., Gao, J., Wang, K., & Li, P. (2017) · BioMed Research International · doi:10.1155/2017/1278436 · Cited by 93
“Similarly, the hypoxia induced early expression of miR146b is cardiomyocyte protective by increasing the expression of NF-kB and STAT3, which play cell survival role [91]. miR214 protects cardiomyocyte cell survival and tissue damage caused by hypoxia and I/R injury by suppressing PTEN expression activating PI3K-Akt m…”
BackgroundInfluentialZhu, W., Wu, R., Lv, Y., Liu, Y., Huang, H., & Xu, J. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109368 · Cited by 95
Chuppa, S., Liang, M., Liu, P., Liu, Y., Casati, M. C., Cowley, A. W., Patullo, L., & Kriegel, A. J. (2018) · Kidney International · doi:10.1016/j.kint.2017.05.014 · Cited by 99
Hsu, A., Chen, S., Chang, Y., Chen, H., & Chu, P. (2014) · BioMed Research International · doi:10.1155/2014/418628 · Cited by 90
“Studies of miRNAs in cardiovascular diseases have mostly been based on tissues of diseasemodels [41, 44, 45, 49] and transgenicmice [39, 40, 44, 46].”
BackgroundMicroRNAs as major regulators of the autophagy pathway
Akkoç, Y., & Gözüaçık, D. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118662 · Cited by 92
Metadata
- Authors
- Ucar, A., Gupta, S. K., Fiedler, J., Erikci, E., Kardasinski, M., Batkai, S., Dangwal, S., Kumarswamy, R., Bang, C., Holzmann, A., Remke, J., Caprio, M., Jentzsch, C., Engelhardt, S., Geisendorf, S., Glas, C., Hofmann, T. G., Nessling, M., Richter, K., Schiffer, M., Carrier, L., Napp, L. C., Bauersachs, J., Chowdhury, K., & Thum, T.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- IRCCS San Raffaele Roma (IT)
- Technical University of Munich (DE)
- Max Planck Institute for Biophysical Chemistry (DE)
- German Cancer Research Center (DE)
- Mount Desert Island Biological Laboratory (US)
- University Medical Center Hamburg-Eppendorf (DE)
- Corresponding author
- Chowdhury, Kamal
- Thum, Thomas
- ORCID
- Venue
- Nature Communications
- Published
- 2012-09-25
- Volume
- 3
- Issue
- 1
- Pages
- 1078-1078
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3657998
- OpenAlex
- W2101080348
- Cited by
- 610
- References
- 46
- Citations by year
- 2026: 19 · 2025: 28 · 2024: 47 · 2023: 32 · 2022: 60 · 2021: 53 · 2020: 52 · 2019: 41 · 2018: 43 · 2017: 51 · 2016: 47 · 2015: 67 · 2014: 44 · 2013: 26
- FWCI
- 28.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature Communications (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
- Funders
- Baden-Württemberg Stiftung
- Deutsches Krebsforschungszentrum
- Deutsche Forschungsgemeinschaft (DFG-TH903/10-1, 01EO0802, SCHI587/3)
- Bundesministerium für Bildung und Forschung (01EO0802)
- Max-Planck-Gesellschaft
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- miR-212, miR-132, cardiac hypertrophy, cardiomyocyte autophagy, heart failure, FOXO3, pressure overload, antagomir, cardiomyocyte-specific overexpression, starvation-induced autophagy
- MeSH terms
- Antagomirs, Animals, Autophagy, Cells, Cultured, Cardiomegaly, Male, Mice, Transgenic, Oligonucleotides, Calcineurin, Reverse Transcriptase Polymerase Chain Reaction, Myocytes, Cardiac, MicroRNAs, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.